Compare BUUU & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUUU | CNTB |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.1M | 128.6M |
| IPO Year | 2025 | 2021 |
| Metric | BUUU | CNTB |
|---|---|---|
| Price | $8.39 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 9.7K | ★ 159.8K |
| Earning Date | 01-06-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $6,328,425.00 | $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | $158.62 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $3.67 | $0.51 |
| 52 Week High | $9.50 | $3.28 |
| Indicator | BUUU | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.83 |
| Support Level | N/A | $2.11 |
| Resistance Level | N/A | $2.65 |
| Average True Range (ATR) | 0.00 | 0.22 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 77.43 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.